Tags

Type your tag names separated by a space and hit enter

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
Depress Anxiety 2004; 19(4):234-40DA

Abstract

Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (18 years or older) who met DSM-IV criteria for GAD, with baseline Hamilton Rating Scale for Anxiety (HAMA) scores > or = 18, were randomly assigned to double blind treatment with escitalopram (10 mg/day for the first 4 weeks and then flexibly dosed from 10-20 mg/day) or placebo for 8 weeks, following a 1-week, single-blind, placebo lead-in period. The primary efficacy variable was the mean change from baseline in total HAMA score at Week 8. The escitalopram group (N = 158) showed a statistically significant, and clinically relevant, greater improvement at endpoint compared with placebo (N = 157) in all prospectively defined efficacy parameters. Significant improvement in HAMA total score and HAMA psychic anxiety subscale score for the escitalopram-treated group vs. the placebo-treated group was observed beginning at Week 1 and at each study visit thereafter. Mean changes from baseline to Week 8 on the HAMA total score using a last-observation-carried-forward (LOCF) approach were -11.3 for escitalopram and -7.4 for placebo (P<.001). Response rates at Week 8 were 68% for escitalopram and 41% for placebo (P<.01) for completers, and 58% for escitalopram and 38% for placebo LOCF values (P<.01). Treatment with escitalopram was well tolerated, with low rates of reported adverse events and an incidence of discontinuation due to adverse events not statistically different from placebo (8.9% vs. 5.1%; P=.27). Escitalopram 10-20 mg/day is effective, safe, and well tolerated in the treatment of patients with GAD.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Science, Duke University Medical Center, Durham, NC 27710, USA. tolme@acpub.duke.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15274172

Citation

Davidson, Jonathan R T., et al. "Escitalopram in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo Controlled, Flexible-dose Study." Depression and Anxiety, vol. 19, no. 4, 2004, pp. 234-40.
Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004;19(4):234-40.
Davidson, J. R., Bose, A., Korotzer, A., & Zheng, H. (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depression and Anxiety, 19(4), pp. 234-40.
Davidson JR, et al. Escitalopram in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo Controlled, Flexible-dose Study. Depress Anxiety. 2004;19(4):234-40. PubMed PMID: 15274172.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. AU - Davidson,Jonathan R T, AU - Bose,Anjana, AU - Korotzer,Andrew, AU - Zheng,Hongjie, PY - 2004/7/27/pubmed PY - 2004/12/16/medline PY - 2004/7/27/entrez SP - 234 EP - 40 JF - Depression and anxiety JO - Depress Anxiety VL - 19 IS - 4 N2 - Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (18 years or older) who met DSM-IV criteria for GAD, with baseline Hamilton Rating Scale for Anxiety (HAMA) scores > or = 18, were randomly assigned to double blind treatment with escitalopram (10 mg/day for the first 4 weeks and then flexibly dosed from 10-20 mg/day) or placebo for 8 weeks, following a 1-week, single-blind, placebo lead-in period. The primary efficacy variable was the mean change from baseline in total HAMA score at Week 8. The escitalopram group (N = 158) showed a statistically significant, and clinically relevant, greater improvement at endpoint compared with placebo (N = 157) in all prospectively defined efficacy parameters. Significant improvement in HAMA total score and HAMA psychic anxiety subscale score for the escitalopram-treated group vs. the placebo-treated group was observed beginning at Week 1 and at each study visit thereafter. Mean changes from baseline to Week 8 on the HAMA total score using a last-observation-carried-forward (LOCF) approach were -11.3 for escitalopram and -7.4 for placebo (P<.001). Response rates at Week 8 were 68% for escitalopram and 41% for placebo (P<.01) for completers, and 58% for escitalopram and 38% for placebo LOCF values (P<.01). Treatment with escitalopram was well tolerated, with low rates of reported adverse events and an incidence of discontinuation due to adverse events not statistically different from placebo (8.9% vs. 5.1%; P=.27). Escitalopram 10-20 mg/day is effective, safe, and well tolerated in the treatment of patients with GAD. SN - 1091-4269 UR - https://www.unboundmedicine.com/medline/citation/15274172/Escitalopram_in_the_treatment_of_generalized_anxiety_disorder:_double_blind_placebo_controlled_flexible_dose_study_ L2 - https://doi.org/10.1002/da.10146 DB - PRIME DP - Unbound Medicine ER -